"After Torrent Pharmaceuticals' Rs 2,004-crore acquisition deal, Elder Pharmaceuticals Ltd (EPL) plans to concentrate and build on its domestic business of anti-infectives, strengthen in-license portfolio and grow its business in the UK and in Europe. It is also exploring the possibility of entering new therapeutics areas," a company statement said here today.
"EPL expects an increase in its consolidated revenues and to re-structure and re-strategise brands and people. EPL would easily increase its revenues and profitability," Elder Pharmaceuticals Chairman and Managing Director Alok Saxena said in the statement.
Formic and its line-extension Formic-O are the key revenue contributors to this division. Newly-launched Balofloxacin, MENY (Meropenem) and Formic OF are expected to boost revenues in this division, the release said.
The company plans to further strengthen its in-license portfolio and increase its presence in the Neurological [CNS] therapeutic and cardio-vascular segments.
EPL plans to concentrate its efforts to increase its presence in injectables and anti-infectives' segments to nearly triple the turnover of its retained business in the next three years. Elder's focus would be on creating a product in a therapeutic category and to establish brand leadership in that segment, apart from developing its own portfolio.